Analysis of the cancer genome atlas sequencing data reveals novel properties of the human papillomavirus 16 genome in head and neck squamous cell carcinoma

Oncotarget

Volumn 8, Issue 11, 2017, Pages 17684-17699

  Nulton, Tara J ^a   Olex, Amy L ^b   Dozmorov, Mikhail ^b   Morgan, Iain M ^a,c   Windle, Brad ^a,c,d  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Genomic structure; Head and neck cancer; HPV16; Integration; TCGA

Indexed keywords

DNA; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; PROTEIN E7; REPRESSOR PROTEIN; VIRUS DNA;

ARTICLE; DNA DETERMINATION; EPISOME; GENE DOSAGE; GENE EXPRESSION; GENE MAPPING; GENOME ANALYSIS; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; NONHUMAN; RNA SEQUENCE; VIRUS GENOME; VIRUS LOAD; WHOLE GENOME SEQUENCING; BIOSYNTHESIS; BOOK; COPY NUMBER VARIATION; GENETIC DATABASE; GENETICS; HEAD AND NECK TUMOR; PAPILLOMAVIRUS INFECTION; SQUAMOUS CELL CARCINOMA; VIROLOGY;

ATLASES AS TOPIC; CARCINOMA, SQUAMOUS CELL; DATABASES, GENETIC; DNA COPY NUMBER VARIATIONS; DNA, VIRAL; GENOME, VIRAL; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS 16; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; REPRESSOR PROTEINS;

EID: 85015175312     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.15179     Document Type: Article

References (53)

1. zur Hausen H. Papillomaviruses in the causation of human cancers-a brief historical account. Virology. 2009; 384(2):260-265.
2. Hebner CM and Laimins LA. Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity. Rev Med Virol. 2006; 16(2):83-97.
3. Thierry F. Transcriptional regulation of the papillomavirus oncogenes by cellular and viral transcription factors in cervical carcinoma. Virology. 2009; 384(2):375-379.
4. Moody CA and Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010; 10(8):550-560.
5. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR and Stanley MA. The biology and life-cycle of human papillomaviruses. Vaccine. 2012; 30 Suppl 5:F55-70.
6. Yasugi T, Benson JD, Sakai H, Vidal M and Howley PM. Mapping and characterization of the interaction domains of human papillomavirus type 16 E1 and E2 proteins. J Virol. 1997; 71(2):891-899.
7. Mohr IJ, Clark R, Sun S, Androphy EJ, MacPherson P and Botchan MR. Targeting the E1 replication protein to the papillomavirus origin of replication by complex formation with the E2 transactivator. Science. 1990; 250(4988):1694-1699.
8. Melendy T, Sedman J and Stenlund A. Cellular factors required for papillomavirus DNA replication. J Virol. 1995; 69(12):7857-7867.
9. Loo YM and Melendy T. Recruitment of replication protein A by the papillomavirus E1 protein and modulation by single-stranded DNA. J Virol. 2004; 78(4):1605-1615.
10. Alazawi W, Pett M, Strauss S, Moseley R, Gray J, Stanley M and Coleman N. Genomic imbalances in 70 snap-frozen cervical squamous intraepithelial lesions: associations with lesion grade, state of the HPV16 E2 gene and clinical outcome. Br J Cancer. 2004; 91(12):2063-2070.
11. Jeon S and Lambert PF. Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. Proc Natl Acad Sci U S A. 1995; 92(5):1654-1658.
12. Romanczuk H and Howley PM. Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity. Proc Natl Acad Sci U S A. 1992; 89(7):3159-3163.
13. Marur S, D'Souza G, Westra WH and Forastiere AA. HPVassociated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010; 11(8):781-789.
14. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP and Gillison ML. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010; 363(1):24-35.
15. Kimple RJ, Smith MA, Blitzer GC, Torres AD, Martin JA, Yang RZ, Peet CR, Lorenz LD, Nickel KP, Klingelhutz AJ, Lambert PF and Harari PM. Enhanced radiation sensitivity in HPV-positive head and neck cancer. Cancer Res. 2013; 73(15):4791-4800.
16. Parfenov M, Pedamallu CS, Gehlenborg N, Freeman SS, Danilova L, Bristow CA, Lee S, Hadjipanayis AG, Ivanova EV, Wilkerson MD, Protopopov A, Yang L, Seth S, Song X, Tang J, Ren X, et al. Characterization of HPV and host genome interactions in primary head and neck cancers. Proc Natl Acad Sci U S A. 2014; 111(43):15544-15549.
17. Munoz N. Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol. 2000; 19(1-2):1-5.
18. Reinson T, Henno L, Toots M, Ustav M, Jr. and Ustav M. The Cell Cycle Timing of Human Papillomavirus DNA Replication. PLoS One. 2015; 10(7):e0131675.
19. Johansson C and Schwartz S. Regulation of human papillomavirus gene expression by splicing and polyadenylation. Nat Rev Microbiol. 2013; 11(4):239-251.
20. Durst M, Kleinheinz A, Hotz M and Gissmann L. The physical state of human papillomavirus type 16 DNA in benign and malignant genital tumours. J Gen Virol. 1985; 66 (Pt 7):1515-1522.
21. Cullen AP, Reid R, Campion M and Lorincz AT. Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. J Virol. 1991; 65(2):606-612.
22. Kristiansen E, Jenkins A and Holm R. Coexistence of episomal and integrated HPV16 DNA in squamous cell carcinoma of the cervix. J Clin Pathol. 1994; 47(3):253-256.
23. Pittayakhajonwut D and Angeletti PC. Analysis of ciselements that facilitate extrachromosomal persistence of human papillomavirus genomes. Virology. 2008; 374(2):304-314.
24. Rogers AJ, Loggen M, Lee K and Angeletti PC. Varying efficiency of long-term replication of papillomaviruses in Saccharomyces cerevisiae. Virology. 2008; 381(1):6-10.
25. Pittayakhajonwut D and Angeletti PC. Viral trans-factor independent replication of human papillomavirus genomes. Virol J. 2010; 7:123.
26. Zheng ZM. Viral oncogenes, noncoding RNAs, and RNA splicing in human tumor viruses. Int J Biol Sci. 2010; 6(7):730-755.
27. Bohm S, Wilczynski SP, Pfister H and Iftner T. The predominant mRNA class in HPV16-infected genital neoplasias does not encode the E6 or the E7 protein. Int J Cancer. 1993; 55(5):791-798.
28. Olthof NC, Speel EJ, Kolligs J, Haesevoets A, Henfling M, Ramaekers FC, Preuss SF, Drebber U, Wieland U, Silling S, Lam WL, Vucic EA, Kremer B, Klussmann JP and Huebbers CU. Comprehensive analysis of HPV16 integration in OSCC reveals no significant impact of physical status on viral oncogene and virally disrupted human gene expression. PLoS One. 2014; 9(2):e88718.
29. Ghittoni R, Accardi R, Hasan U, Gheit T, Sylla B and Tommasino M. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes. 2010; 40(1):1-13.
30. Williams VM, Filippova M, Filippov V, Payne KJ and Duerksen-Hughes P. Human papillomavirus type 16 E6* induces oxidative stress and DNA damage. J Virol. 2014; 88(12):6751-6761.
31. Tang S, Tao M, McCoy JP, Jr. and Zheng ZM. The E7 oncoprotein is translated from spliced E6*I transcripts in high-risk human papillomavirus type 16-or type 18-positive cervical cancer cell lines via translation reinitiation. J Virol. 2006; 80(9):4249-4263.
32. de Boer MA, Jordanova ES, Kenter GG, Peters AA, Corver WE, Trimbos JB and Fleuren GJ. High human papillomavirus oncogene mRNA expression and not viral DNA load is associated with poor prognosis in cervical cancer patients. Clin Cancer Res. 2007; 13(1):132-138.
33. Cricca M, Morselli-Labate AM, Venturoli S, Ambretti S, Gentilomi GA, Gallinella G, Costa S, Musiani M and Zerbini M. Viral DNA load, physical status and E2/E6 ratio as markers to grade HPV16 positive women for high-grade cervical lesions. Gynecol Oncol. 2007; 106(3):549-557.
34. Yoshida T, Sano T, Kanuma T, Owada N, Sakurai S, Fukuda T and Nakajima T. Quantitative real-time polymerase chain reaction analysis of the type distribution, viral load, and physical status of human papillomavirus in liquid-based cytology samples from cervical lesions. Int J Gynecol Cancer. 2008; 18(1):121-127.
35. Guo M, Sneige N, Silva EG, Jan YJ, Cogdell DE, Lin E, Luthra R and Zhang W. Distribution and viral load of eight oncogenic types of human papillomavirus (HPV) and HPV 16 integration status in cervical intraepithelial neoplasia and carcinoma. Mod Pathol. 2007; 20(2):256-266.
36. Cheung JL, Lo KW, Cheung TH, Tang JW and Chan PK. Viral load, E2 gene disruption status, and lineage of human papillomavirus type 16 infection in cervical neoplasia. J Infect Dis. 2006; 194(12):1706-1712.
37. Sathish N, Abraham P, Peedicayil A, Sridharan G, John S and Chandy G. Human papillomavirus 16 E6/E7 transcript and E2 gene status in patients with cervical neoplasia. Mol Diagn. 2004; 8(1):57-64.
38. Kalantari M, Blennow E, Hagmar B and Johansson B. Physical state of HPV16 and chromosomal mapping of the integrated form in cervical carcinomas. Diagn Mol Pathol. 2001; 10(1):46-54.
39. Ramqvist T, Mints M, Tertipis N, Nasman A, Romanitan M and Dalianis T. Studies on human papillomavirus (HPV) 16 E2, E5 and E7 mRNA in HPV-positive tonsillar and base of tongue cancer in relation to clinical outcome and immunological parameters. Oral Oncol. 2015; 51(12):1126-1131.
40. Hwang ES, Naeger LK and DiMaio D. Activation of the endogenous p53 growth inhibitory pathway in HeLa cervical carcinoma cells by expression of the bovine papillomavirus E2 gene. Oncogene. 1996; 12(4):795-803.
41. DeFilippis RA, Goodwin EC, Wu L and DiMaio D. Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence, and apoptosis in HeLa cervical carcinoma cells. J Virol. 2003; 77(2):1551-1563.
42. Nishimura A, Ono T, Ishimoto A, Dowhanick JJ, Frizzell MA, Howley PM and Sakai H. Mechanisms of human papillomavirus E2-mediated repression of viral oncogene expression and cervical cancer cell growth inhibition. J Virol. 2000; 74(8):3752-3760.
43. Parish JL, Kowalczyk A, Chen HT, Roeder GE, Sessions R, Buckle M and Gaston K. E2 proteins from high-and low-risk human papillomavirus types differ in their ability to bind p53 and induce apoptotic cell death. J Virol. 2006; 80(9):4580-4590.
44. White PW, Faucher AM, Massariol MJ, Welchner E, Rancourt J, Cartier M and Archambault J. Biphenylsulfonacetic acid inhibitors of the human papillomavirus type 6 E1 helicase inhibit ATP hydrolysis by an allosteric mechanism involving tyrosine 486. Antimicrob Agents Chemother. 2005; 49(12):4834-4842.
45. White PW, Titolo S, Brault K, Thauvette L, Pelletier A, Welchner E, Bourgon L, Doyon L, Ogilvie WW, Yoakim C, Cordingley MG and Archambault J. Inhibition of human papillomavirus DNA replication by small molecule antagonists of the E1-E2 protein interaction. J Biol Chem. 2003; 278(29):26765-26772.
46. Wilks C, Cline MS, Weiler E, Diehkans M, Craft B, Martin C, Murphy D, Pierce H, Black J, Nelson D, Litzinger B, Hatton T, Maltbie L, Ainsworth M, Allen P, Rosewood L, et al. The Cancer Genomics Hub (CGHub): overcoming cancer through the power of torrential data. Database (Oxford). 2014; 2014.
47. Van Doorslaer K, Tan Q, Xirasagar S, Bandaru S, Gopalan V, Mohamoud Y, Huyen Y and McBride AA. The Papillomavirus Episteme: a central resource for papillomavirus sequence data and analysis. Nucleic Acids Res. 2013; 41(Database issue):D571-578.
48. Langmead B and Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012; 9(4):357-359.
49. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G and Durbin R. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009; 25(16):2078-2079.
50. Quinlan AR and Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010; 26(6):841-842.
51. Okonechnikov K, Golosova O and Fursov M. Unipro UGENE: a unified bioinformatics toolkit. Bioinformatics. 2012; 28(8):1166-1167.
52. Tatusova T, Ciufo S, Fedorov B, O'Neill K and Tolstoy I. RefSeq microbial genomes database: new representation and annotation strategy. Nucleic Acids Res. 2014; 43(7):3872.
53. Trapnell C, Pachter L and Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics. 2009; 25(9):1105-1111.